Nikolai Kley
Vorstandsvorsitzender bei Orionis Biosciences BV
Profil
Nikolai Kley is the founder of two companies, FORMA Therapeutics, Inc. (founded in 2008) and Orionis Biosciences, Inc. (founded in 2015).
At FORMA Therapeutics, he held the title of VP-Biology & Head-Drug Discovery Research from 2008 to 2011.
At Orionis Biosciences, he held the titles of President, Chief Executive Officer & Director from 2015 to present, and currently holds the titles of Managing Director & Director at Orionis Biosciences BV since 2015 and Professor at Princeton University.
He previously worked at Bristol Myers Squibb Co. as a Principal, GPC Biotech AG as a Vice President, The General Hospital Corp.
as a Fellow, Genome Therapeutics Corp.
as a Vice President, and Harvard Medical School as a Fellow.
He received his undergraduate degree from the University of Leeds and doctorate degrees from Max-Planck-Institute for Molecular Genetics and Ludwig-Maximilians-Universität München.
Aktive Positionen von Nikolai Kley
| Unternehmen | Position | Beginn |
|---|---|---|
| Princeton University | Corporate Officer/Principal | 28.06.2011 |
Orionis Biosciences, Inc.
 Orionis Biosciences, Inc. Packaged SoftwareTechnology Services Orionis Biosciences, Inc. engages in operation of an biotechnology company that specializes in drug discovery. It offers A-Kine biologics and Allo-Glue, a small molecule platform with applications to the reprogramming of disease states. The company was founded by Nikolai Kley and Jan Tavernier and is headquartered in Waltham, MA. | Gründer | 01.01.2015 |
Orionis Biosciences BV
 Orionis Biosciences BV Pharmaceuticals: MajorHealth Technology Part of Orionis Biosciences, Inc., Orionis Biosciences BV operates as a drug discovery and Belgian development biotechnology company. The company is based in Ghent, Belgium. The company was founded in 2015. Nikolai Kley has been the CEO of the company since 2015. | Vorstandsvorsitzender | 09.11.2020 |
Ehemalige bekannte Positionen von Nikolai Kley
| Unternehmen | Position | Ende |
|---|---|---|
| Harvard Medical School | Corporate Officer/Principal | - |
The General Hospital Corp.
 The General Hospital Corp. Hospital/Nursing ManagementHealth Services The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA. | Corporate Officer/Principal | - |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
| Genome Therapeutics Corp. /Genomevision Services Unit/ | Corporate Officer/Principal | - |
GPC Biotech AG
 GPC Biotech AG Miscellaneous Commercial ServicesCommercial Services GPC Biotech AG is a biotechnology company discovering and developing new anticancer drugs.It is headquartered in Martinsried/Munich (Germany). The Company's wholly owned U.S. subsidiary has research and development sites in Waltham, Massachusetts and Princeton, New Jersey | Corporate Officer/Principal | - |
Ausbildung von Nikolai Kley
| University of Leeds | Undergraduate Degree |
| Max-Planck-Institute for Molecular Genetics | Doctorate Degree |
| Ludwig-Maximilians-Universität München | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Private Unternehmen | 6 |
|---|---|
FORMA Therapeutics, Inc.
 FORMA Therapeutics, Inc. BiotechnologyHealth Technology FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA. | Health Technology |
GPC Biotech AG
GPC Biotech AG Miscellaneous Commercial ServicesCommercial Services GPC Biotech AG is a biotechnology company discovering and developing new anticancer drugs.It is headquartered in Martinsried/Munich (Germany). The Company's wholly owned U.S. subsidiary has research and development sites in Waltham, Massachusetts and Princeton, New Jersey | Commercial Services |
The General Hospital Corp.
The General Hospital Corp. Hospital/Nursing ManagementHealth Services The General Hospital Corp. provides healthcare services. It offers diagnostic and therapeutic are in every specialty and subspecialty of medicine and surgery. The firm's care center provides cancer, digestive disorders, heart disease, transplantation and vascular medicine services. The company was founded in 1811 and is headquartered in Boston, MA. | Health Services |
| Genome Therapeutics Corp. /Genomevision Services Unit/ | Commercial Services |
Orionis Biosciences, Inc.
Orionis Biosciences, Inc. Packaged SoftwareTechnology Services Orionis Biosciences, Inc. engages in operation of an biotechnology company that specializes in drug discovery. It offers A-Kine biologics and Allo-Glue, a small molecule platform with applications to the reprogramming of disease states. The company was founded by Nikolai Kley and Jan Tavernier and is headquartered in Waltham, MA. | Technology Services |
Orionis Biosciences BV
Orionis Biosciences BV Pharmaceuticals: MajorHealth Technology Part of Orionis Biosciences, Inc., Orionis Biosciences BV operates as a drug discovery and Belgian development biotechnology company. The company is based in Ghent, Belgium. The company was founded in 2015. Nikolai Kley has been the CEO of the company since 2015. | Health Technology |
